CELL CULTURE 


Manufacture and logistics of next generation therapeutics 

From cell and gene therapies to biosimilars, ADCs, antibody fragments, vaccines and much more we will be exploring the challenges in manufacture and logistics for these exciting new formats and applying them in case studies from the very best in the industry. This year we will be covering topics within manufacture of viral vectors, strategies for cultivating stem cells, cell and gene therapy production, manufacturing, formulation and product delineation.

Continuous manufacture 


Many of the current blockbusters will be “running out of patent” during the next few years and there will be less, or even no blockbusters due to a shift towards stratified medicine. The trend towards stratified therapeutics will support a change in plant design aiming for highly flexible multi-purpose facilities for small production volumes.

CRISPR / Cell line development 


As CRISPR becomes more and more widely used, and the technology more understood, this year we’re going to be exploring more applications of this industry changing technology, and discuss methods in how we can use this technology to propel us forwards. Cell line development will also be discussed, moving away from the more traditional CHO cell lines, to see new methods of producing cell lines and changing the ones we already have.


Visionaries speaking on this topic include

Berthold Bödeker
                         Berthold Bödeker
                 Chief Scientist, Global Drug                 Discovery – Global Biologics Biotech                                             Development
                         Bayer Pharma AG


Mark D. Angelino
                     Mark D. Angelino
          Senior Vice President,                                     Pharmaceutical  Sciences
                       Bluebird Bio

Holger Laux
                              Holger Laux
                                 Fellow

                                Novartis



Otto Wilhelm-Merten
                     Otto Wilhelm-Merten
              Head of Applied Vectorology and                                 Innovation group
                               Genethon

Hitto Kaufmann
                       Hitto Kaufmann
 Global Vice President of Biopharmaceutical         Development and Platform Innovation
                              Sanofi



Thomas Wucherpfennig
                Thomas Wucherpfennig
          Associate Director, Late Stage Cell                              Culture Development
                 Boehringer Ingelheim

DOWNLOAD THE BROCHURE